IRON vs. LQDA, CABA, LSEA, QSI, PBYI, BHVN, HCM, CORT, RARE, and MRUS
Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Liquidia (LQDA), Cabaletta Bio (CABA), Landsea Homes (LSEA), Quantum-Si (QSI), Puma Biotechnology (PBYI), Biohaven (BHVN), HUTCHMED (HCM), Corcept Therapeutics (CORT), Ultragenyx Pharmaceutical (RARE), and Merus (MRUS).
Disc Medicine (NASDAQ:IRON) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Disc Medicine presently has a consensus price target of $57.71, suggesting a potential upside of 66.52%. Liquidia has a consensus price target of $21.00, suggesting a potential upside of 70.87%. Given Liquidia's higher probable upside, analysts plainly believe Liquidia is more favorable than Disc Medicine.
83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Comparatively, 31.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Liquidia received 158 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 75.00% of users gave Disc Medicine an outperform vote while only 66.55% of users gave Liquidia an outperform vote.
Disc Medicine has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Disc Medicine has higher earnings, but lower revenue than Liquidia. Disc Medicine is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Disc Medicine has a net margin of 0.00% compared to Liquidia's net margin of -674.42%. Disc Medicine's return on equity of -22.81% beat Liquidia's return on equity.
In the previous week, Disc Medicine had 6 more articles in the media than Liquidia. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Liquidia. Liquidia's average media sentiment score of 1.45 beat Disc Medicine's score of 0.78 indicating that Liquidia is being referred to more favorably in the news media.
Summary
Disc Medicine beats Liquidia on 10 of the 17 factors compared between the two stocks.
Get Disc Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Disc Medicine Competitors List
Related Companies and Tools
